Research Summary1. IRB approved protocol to develop Face Transplantation: Member of Transplant Team involved in the development of immunosuppressive protocol, and the postoperative management, for the first Face Transplant performed in New England, only the second in the United States and the seventh world wide. (Role: Co- Investigator)
2. Comparison of Kidney Volume by MDCT Versus Split Function Testing to Determine Choice of Kidney for Living Donor Kidney Transplantation.Protocol #2009-P-000275/1. (Role: Principal Investigator)
3. Transplant of Allograft Face or Facial Subunit for Treatment of Burn or Cancer Related Facial Defects in Transplanted Patients. Protocol #2006-P-002286/2. Sponsor: Department Funds (Role: Co-Investigator)
4. Predictors of Health after Donor Nephrectomy. Protocol #2008-P-001050/10. Sposor: Department Funds. (Role: Co-Investigator) 5. Characterization of Immunological profile of Renal Transplant patients Undergoing Induction Treatment With Thymoglobuliun Vs IL-2 Receptor Antagonist Basiliximab. Protocol #2008-P-00074/1. Sponsor: Genzyme Corporation. (Role: Co-Investigator) 6. A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in De Novo Kidney Transplant. Protocol #2008-P-000412/11. Sponsor: Astellas Pharma US, Inc. (Role: Co-Investigator) 7. Renal transplantation in Patients with Positive Lymphocytotoxicity Crossmatches: One Center’s Experience. Protocol #2008-P-000074/1. (Role: Co-Investigator) 8. Pathophysiology of Aortic Aneurysm. Protocol #2005-P-002166/7. (Role: Co-Investigator) 9. The Development of Immunemonitoring Assays in Renal Transplant Recipients. Protocol #2008-P-000070/7. Sponsor: NIH/NIAID. (Role: Co-Investigator) 10. CTOT-02/CCTPT-02 B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop de novo Anti-HLA Alloantibodies will Result in Inhibition of Alloantibody Production and Attenuation of Chronic Humoral Rejection (Role: Co-Investigator) Back to the top | 
Send Feedback to: 
